Recent developments in understanding epidemiology and risk determinants of atrial fibrillation as a cause of stroke

Canadian Journal of Cardiology

Volumn 29, Issue 7 SUPPL, 2013, Pages

  Ahmad, Yousif ^a   Lip, Gregory Y H ^a   Lane, Deirdre A ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; DABIGATRAN; PLACEBO; RIVAROXABAN; WARFARIN;

ANTICOAGULATION; CEREBROVASCULAR ACCIDENT; HEART ATRIUM FIBRILLATION; HUMAN; PATHOPHYSIOLOGY; PREVALENCE; REVIEW; RISK FACTOR; SLEEP DISORDERED BREATHING;

EID: 84879516150     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2013.03.009     Document Type: Review

References (93)

1. Lip G.Y., Tse H.F., Lane D.A. Atrial fibrillation. Lancet 2012, 379:648-661.
2. Lloyd-Jones D.M., Wang T.J., Leip E.P., et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004, 110:1042-1046.
3. Savelieva I., Camm A.J. Clinical trends in atrial fibrillation at the turn of the millennium. JIntern Med 2001, 250:369-372.
4. Miyasaka Y., Barnes M.E., Gersh B.J., et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006, 114:119-125.
5. Kannel W.B., Wolf P.A., Benjamin E.J., Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998, 82:2N-9N.
6. Benjamin E.J., Wolf P.A., D'Agostino R.B., Silbershatz H., Kannel W.B., Levy D. Impact of atrial fibrillation on the risk of death: the Framingham heart study. Circulation 1998, 98:946-952.
7. Dulli D.A., Stanko H., Levine R.L. Atrial fibrillation is associated with severe acute ischemic stroke. Neuroepidemiology 2003, 22:118-123.
8. Piccini J.P., Hammill B.G., Sinner M.F., et al. Incidence and prevalence of atrial fibrillation and associated mortality among Medicare beneficiaries, 1993-2007. Circ Cardiovasc Qual Outcomes 2012, 5:85-93.
9. Wolf P.A., Abbott R.D., Kannel W.B. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke 1991, 22:983-988.
10. Stewart S., Murphy N., Walker A., McGuire A., McMurray J.J. Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. Heart 2004, 90:286-292.
11. Kim M.H., Johnson S.S., Chu B.C., Dalal M.R., Schulman K.L. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. Circ Cardiovasc Qual Outcomes 2011, 4:313-320.
12. Kirchhof P., Lip G.Y., van Gelder I.C., et al. Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options-a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. Europace 2012, 14:8-27.
13. Hart R.G., Pearce L.A., Aguilar M.I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007, 146:857-867.
14. Mant J., Hobbs F.D., Fletcher K., et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007, 370:493-503.
15. Gallagher A.M., Setakis E., Plumb J.M., Clemens A., van Staa T.P. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost 2011, 106:968-977.
16. Gage B.F., Waterman A.D., Shannon W., Boechler M., Rich M.W., Radford M.J. Validation of clinical classification schemes for predicting stroke: results from the national registry of atrial fibrillation. JAMA 2001, 285:2864-2870.
17. Benjamin E.J., Levy D., Vaziri S.M., D'Agostino R.B., Belanger A.J., Wolf P.A. Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham Heart Study. JAMA 1994, 271:840-844.
18. Benjamin E.J., Chen P.S., Bild D.E., et al. Prevention of atrial fibrillation: report from a national heart, lung, and blood institute workshop. Circulation 2009, 119:606-618.
19. Cosio F.G., Aliot E., Botto G.L., et al. Delayed rhythm control of atrial fibrillation may be a cause of failure to prevent recurrences: reasons for change to active antiarrhythmic treatment at the time of the first detected episode. Europace 2008, 10:21-27.
20. Huxley R.R., Lopez F.L., Folsom A.R., et al. Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2011, 123:1501-1508.
21. Schnabel R.B., Sullivan L.M., Levy D., et al. Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. Lancet 2009, 373:739-745.
22. Aviles R.J., Martin D.O., Apperson-Hansen C., et al. Inflammation as a risk factor for atrial fibrillation. Circulation 2003, 108:3006-3010.
23. Krahn A.D., Manfreda J., Tate R.B., Mathewson F.A., Cuddy T.E. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 1995, 98:476-484.
24. Marcus G.M., Alonso A., Peralta C.A., et al. Candidate-Gene Association Resource (CARe) Study. European ancestry as a risk factor for atrial fibrillation in African Americans. Circulation 2010, 122:2009-2015.
25. Chamberlain A.M., Agarwal S.K., Folsom A.R., et al. Aclinical risk score for atrial fibrillation in a biracial prospective cohort (from the Atherosclerosis Risk in Communities [ARIC] study). Am J Cardiol 2011, 107:85-91.
26. Furberg C.D., Psaty B.M., Manolio T.A., Gardin J.M., Smith V.E., Rautaharju P.M. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol 1994, 74:236-241.
27. de Vos C.B., Pisters R., Nieuwlaat R., et al. Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. JAm Coll Cardiol 2010, 55:725-731.
28. Conen D., Tedrow U.B., Koplan B.A., Glynn R.J., Buring J.E., Albert C.M. Influence of systolic and diastolic blood pressure on the risk of incident atrial fibrillation in women. Circulation 2009, 119:2146-2152.
29. Thomas M.C., Dublin S., Kaplan R.C., et al. Blood pressure control and risk of incident atrial fibrillation. Am J Hypertens 2008, 21:1111-1116.
30. Feinberg W.M., Blackshear J.L., Laupacis A., Kronmal R., Hart R.G. Prevalence, age distribution, and gender of patients with atrial fibrillation: analysis and implications. Arch Intern Med 1995, 155:469-473.
31. Gami A.S., Hodge D.O., Herges R.M., et al. Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation. JAm Coll Cardiol 2007, 49:565-571.
32. Psaty B.M., Manolio T.A., Kuller L.H., et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation 1997, 96:2455-2461.
33. Verdecchia P., Reboldi G., Gattobigio R., et al. Atrial fibrillation in hypertension: predictors and outcome. Hypertension 2003, 41:218-223.
34. Gammage M.D., Parle J.V., Holder R.L., et al. Association between serum free thyroxine concentration and atrial fibrillation. Arch Intern Med 2007, 167:928-934.
35. US Population Projections, US Census Bureau. Available at: Accessed January 2, 2013. http://www.census.gov/population/projections/.
36. Spach M.S., Heidlage J.F., Dolber P.C., Barr R.C. Mechanism of origin of conduction disturbances in aging human atrial bundles: experimental and model study. Heart Rhythm 2007, 4:175-185.
37. Lane D.A., Lip G.Y. Female gender is a risk factor for stroke and thromboembolism in atrial fibrillation patients. Thromb Haemost 2009, 101:802-805.
38. Olsson L.G., Swedberg K., Ducharme A., et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. JAm Coll Cardiol 2006, 47:1997-2004.
39. Shotan A., Garty M., Blondhein D.S., et al. Atrial fibrillation and long-term prognosis in patients hospitalized for heart failure: results from heart failure survey in Israel (HFSIS). Eur Heart J 2010, 31:309-317.
40. Tsang T.S., Gersh B.J., Appleton C.P., et al. Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. JAm Coll Cardiol 2002, 40:1636-1644.
41. Dublin S., Glazer N.L., Smith N.L., et al. Diabetes mellitus, glycemic control, and risk of atrial fibrillation. JGen Intern Med 2010, 25:853-858.
42. Sawin C.T., Geller A., Wolf P., et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. NEngl J Med 1994, 331:1249-1252.
43. Heeringa J., Hoogendoorn E.H., van der Deure W.M., et al. High-normal thyroid function and risk of atrial fibrillation: the Rotterdam study. Arch Intern Med 2008, 168:2219-2224.
44. Rosengren A., Hauptman P.J., Lappas G., Olsson L., Wilhelmsen L., Swedberg K. Big men and atrial fibrillation: effects of body size and weight gain on risk of atrial fibrillation in men. Eur Heart J 2009, 30:1113-1120.
45. Tedrow U.B., Conen D., Ridker P.M., et al. The long- and short-term impact of elevated body mass index on the risk of new atrial fibrillation the WHS (Women's Health Study). JAm Coll Cardiol 2010, 55:2319-2327.
46. Frost L., Hune L.J., Vestergaard P. Overweight and obesity as risk factors for atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study. Am J Med 2005, 118:489-495.
47. Wang T.J., Parise H., Levy D., et al. Obesity and the risk of new-onset atrial fibrillation. JAMA 2004, 292:2471-2477.
48. Baber U., Howard V.J., Halperin J.L., et al. Association of chronic kidney disease with atrial fibrillation among adults in the United States: Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Circ Arrhythm Electrophysiol 2011, 4:26-32.
49. Horio T., Iwashima Y., Kamide K., et al. Chronic kidney disease as an independent risk factor for new-onset atrial fibrillation in hypertensive patients. JHypertens 2010, 28:1738-1744.
50. Asselbergs F.W., van den Berg M.P., Diercks G.F., van Gilst W.H., van Veldhuisen D.J. C-reactive protein and microalbuminuria are associated with atrial fibrillation. Int J Cardiol 2005, 98:73-77.
51. Molina L., Mont L., Marrugat J., et al. Long-term endurance sport practice increases the incidence of lone atrial fibrillation in men: a follow-up study. Europace 2008, 10:618-623.
52. Abdulla J., Nielsen J.R. Is the risk of atrial fibrillation higher in athletes than in the general population? A systematic review and meta-analysis. Europace 2009, 11:1156-1159.
53. Aizer A., Gaziano J.M., Cook N.R., Manson J.E., Buring J.E., Albert C.M. Relation of vigorous exercise to risk of atrial fibrillation. Am J Cardiol 2009, 103:1572-1577.
54. Mont L., Tamborero D., Elosua R., et al. Physical activity, height, and left atrial size are independent risk factors for lone atrial fibrillation in middle-aged healthy individuals. Europace 2008, 10:15-20.
55. Elosua R., Arquer A., Mont L., et al. Sport practice and the risk of lone atrial fibrillation: a case-control study. Int J Cardiol 2006, 108:332-337.
56. Stritzke J., Markus M.R., Duderstadt S., et al. The aging process of the heart: obesity is the main risk factor for left atrial enlargement during aging the MONICA/KORA (monitoring of trends and determinations in cardiovascular disease/cooperative research in the region of Augsburg) study. JAm Coll Cardiol 2009, 54:1982-1989.
57. Batal O., Schoenhagen P., Shao M., et al. Left atrial epicardial adiposity and atrial fibrillation. Circ Arrhythm Electrophysiol 2010, 3:230-236.
58. Thanassoulis G., Massaro J.M., O'Donnell C.J., et al. Pericardial fat is associated with prevalent atrial fibrillation: the Framingham Heart Study. Circ Arrhythm Electrophysiol 2010, 3:345-350.
59. Thanassoulis G., Massaro J.M., Hoffmann U., et al. Prevalence, distribution, and risk factor correlates of high pericardial and intrathoracic fat depots in the Framingham heart study. Circ Cardiovasc Imaging 2010, 3:559-566.
60. Gami A.S., Pressman G., Caples S.M., et al. Association of atrial fibrillation and obstructive sleep apnea. Circulation 2004, 110:364-367.
61. Genovesi S., Pogliani D., Faini A., et al. Prevalence of atrial fibrillation and associated factors in a population of long-term hemodialysis patients. Am J Kidney Dis 2005, 46:897-902.
62. Iguchi Y., Kimura K., Kobayashi K., et al. Relation of atrial fibrillation to glomerular filtration rate. Am J Cardiol 2008, 102:1056-1059.
63. Go A.S., Fang M.C., Udaltsova N., et al. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation 2009, 119:1363-1369.
64. Kodama S., Saito K., Tanaka S., et al. Alcohol consumption and risk of atrial fibrillation: a meta-analysis. JAm Coll Cardiol 2011, 57:427-436.
65. Conen D., Tedrow U.B., Cook N.R., Moorthy M.V., Buring J.E., Albert C.M. Alcohol consumption and risk of incident atrial fibrillation in women. JAMA 2008, 300:2489-2496.
66. Mukamal K.J., Tolstrup J.S., Friberg J., Jensen G., Grønbaek M. Alcohol consumption and risk of atrial fibrillation in men and women: the Copenhagen City Heart Study. Circulation 2005, 112:1736-1742.
67. Krishnamoorthy S., Lip G.Y., Lane D.A. Alcohol and illicit drug use as precipitants of atrial fibrillation in young adults: a case series and literature review. Am J Med 2009, 122:851-856.
68. Mozaffarian D., Furberg C.D., Psaty B.M., Siscovick D. Physical activity and incidence of atrial fibrillation in older adults: the cardiovascular health study. Circulation 2008, 118:800-807.
69. Everett B.M., Conen D., Buring J.E., Moorthy M.V., Lee I.M., Albert C.M. Physical activity and the risk of incident atrial fibrillation in women. Circ Cardiovasc Qual Outcomes 2011, 4:321-327.
70. Murphy M.H., Nevill A.M., Murtagh E.M., Holder R.L. The effect of walking on fitness, fatness and resting blood pressure: a meta-analysis of randomised, controlled trials. Prev Med 2007, 44:377-385.
71. Whelton S.P., Chin A., Xin X., He J. Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. Ann Intern Med 2002, 136:493-503.
72. Tanasescu M., Leitzmann M.F., Rimm E.B., Willett W.C., Stampfer M.J., Hu F.B. Exercise type and intensity in relation to coronary heart disease in men. JAMA 2002, 288:1994-2000.
73. Conen D., Ridker P.M., Everett B.M., et al. Amultimarker approach to assess the influence of inflammation on the incidence of atrial fibrillation in women. Eur Heart J 2010, 31:1730-1736.
74. Schnabel R.B., Larson M.G., Yamamoto J.F., et al. Relations of biomarkers of distinct pathophysiological pathways and atrial fibrillation incidence in the community. Circulation 2010, 121:200-207.
75. Smith J.G., Newton-Cheh C., Almgren P., et al. Assessment of conventional cardiovascular risk factors and multiple biomarkers for the prediction of incident heart failure and atrial fibrillation. JAm Coll Cardiol 2010, 56:1712-1719.
76. Latini R., Masson S., Pirelli S., et al. Circulating cardiovascular biomarkers in recurrent atrial fibrillation: data from the GISSI-Atrial Fibrillation Trial. JIntern Med 2011, 269:160-171.
77. Marott S.C., Nordestgaard B.G., Zacho J., et al. Does elevated C-reactive protein increase atrial fibrillation risk? A Mendelian randomization of 47,000 individuals from the general population. JAm Coll Cardiol 2010, 56:789-795.
78. Hart R.G., Pearce L.A., McBride R., Rothbart R.M., Asinger R.W. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. Stroke 1999, 30:1223-1229. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators.
79. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology 2007, 69:546-554. Stroke Risk in Atrial Fibrillation Working Group.
80. Risk factors for thromboembolism during aspirin therapy in patients with atrial fibrillation: the Stroke Prevention in Atrial Fibrillation Study. JStroke Cerebrovasc Dis 1995, 5:147-157. Stroke Prevention in Atrial Fibrillation Investigators.
81. Hughes M., Lip G.Y. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost 2008, 99:295-304. Guideline Development Group, National Clinical Guideline for Management of Atrial Fibrillation in Primary and Secondary CareNational Clinical Guideline for Management of Atrial Fibrillation in Primary and Secondary Care, National Institute for Health and Clinical ExcellenceNational Institute for Health and Clinical Excellence.
82. Avgil Tsadok M., Jackevicius C.A., Rahme E., Humphries K.H., Behlouli H., Pilote L. Sex differences in stroke risk among older patients with recently diagnosed atrial fibrillation. JAMA 2012, 307:1952-1958.
83. Friberg L., Rosenqvist M., Lip G.Y. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182, 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J 2012, 33:1500-1510.
84. Olesen J.B., Lip G.Y., Lane D.A., et al. Vascular disease and stroke risk in atrial fibrillation: a nationwide cohort study. Am J Med 2012, 125. 826.e13-23.
85. Olesen J.B., Fauchier L., Lane D.A., Taillandier S., Lip G.Y. Risk factors for stroke and thromboembolism in relation to age among patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. Chest 2012, 141:147-153.
86. Olesen J.B., Lip G.Y., Kamper A.L., et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. NEngl J Med 2012, 367:625-635.
87. Piccini J.P., Stevens S.R., Chang Y., et al. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 Index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) Study Cohorts. Circulation 2013, 127:224-232.
88. Roldán V., Marín F., Fernández H., et al. Renal impairment in a "real-life" cohort of anticoagulated patients with atrial fibrillation (implications for thromboembolism and bleeding). Am J Cardiol 2013, 111:1159-1164.
89. Lip G.Y. Chronic renal disease and stroke in atrial fibrillation: balancing the prevention of thromboembolism and bleeding risk. Europace 2011, 13:145-148.
90. Lip G.Y., Nieuwlaat R., Pisters R., Lane D.A., Crijns H.J. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest 2010, 137:263-272.
91. Olesen J.B., Lip G.Y., Hansen M.L., et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 2011, 342:d124.
92. Skanes A.C., Healey J.S., Cairns J.A., et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol 2012, 28:125-136.
93. Camm A.J., Lip G.Y., De Caterina R., et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012, 33:2719-2747.